title: An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.
abstract: An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.
authors: Department of Internal Medicine, Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Suite Y3.206, Dallas, TX 75390-9047, USA.
authors: Scott M
authors: SM
authors: Grundy
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D008078:Cholesterol, LDL / Q000097:blood; D004032:Diet; D050171:Dyslipidemias / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications / Q000175:diagnosis; D012307:Risk Factors; D012955:Societies, Medical
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL
keywords: Atherosclerosis; Cardiovascular risk; Cholesterol; Lifestyle therapies; Lipoproteins; Statins